INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market purchaseVerified data

Bitterman Robert J bought PHIO

Director, Chairman, Pres. & CEO · Phio Pharmaceuticals Corp. · Common Stock, $.0001 par value

Side
BUY
Value
$5,100
Shares
5,000
Price
$1.02
Executed
Dec 23, 2025
Disclosed
Dec 29, 2025
Disclosure timeline6 days from execution to publication · legal deadline 2 business days
Dec 23 executedDec 29, 2025 disclosed

PHIO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
35/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+1 / 25

    $5K reported value · 1.8% of prior position

  • Filing timing+6 / 15

    Disclosed 4 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PHIO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    39
    PT
    Plott Ronald ToddDirector
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$5,200
    5,000 sh
    		Sep 29, 2026Sep 30, 2026
    traded Sep 29, 2026
    		+1dSEC FORM 4

    Evidence

    39
    PT
    Plott Ronald ToddDirector
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$5,150
    5,000 sh
    		Sep 28, 2026Sep 30, 2026
    traded Sep 28, 2026
    		+2dSEC FORM 4

    Evidence

    17
    PT
    Plott Ronald ToddDirector
    PHIOPhio Pharmaceuticals Corp.
    Grant or award
    		A—
    17.0K sh
    		Sep 28, 2026Sep 29, 2026
    traded Sep 28, 2026
    		+1dSEC FORM 4

    Evidence

    17
    BJ
    Bitterman Robert JDirector, Chairman, Pres. & CEO
    PHIOPhio Pharmaceuticals Corp.
    Grant or award
    		A—
    400.0K sh
    		Sep 28, 2026Sep 29, 2026
    traded Sep 28, 2026
    		+1dSEC FORM 4

    Evidence

    21
    CC
    Carson Lisa CabottChief Financial Officer
    PHIOPhio Pharmaceuticals Corp.
    Grant or award
    		A—
    108.0K sh
    		Sep 28, 2026Sep 29, 2026
    traded Sep 28, 2026
    		+1dSEC FORM 4

    Evidence

    43
    BA
    Bradford Patricia ADirector
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$6,583
    6,500 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    35
    BJ
    Bitterman Robert JDirector, Chairman, Pres. & CEO
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$2,058
    2,000 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    41
    PT
    Plott Ronald ToddDirector
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$17K
    15.0K sh
    		Aug 19, 2026Aug 20, 2026
    traded Aug 19, 2026
    		+1dSEC FORM 4

    Evidence

    25
    BJ
    Bitterman Robert JDirector, Chairman, Pres. & CEO
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$9,900
    10.0K sh
    		Jun 26, 2026Jun 29, 2026
    traded Jun 26, 2026
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001683168-25-009349
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 23, 2025
    Published
    Dec 29, 2025
    Ingested by INSIDER
    Nov 5, 04:25 UTC
    Last re-read
    Nov 5, 04:25 UTC

    Extracted facts

    Filer
    Bitterman Robert J
    Role
    Director, Chairman, Pres. & CEO
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    Phio Pharmaceuticals Corp.
    Ticker
    PHIO
    Shares
    5,000
    Price per share
    $1.02
    Value
    $5,100
    Execution date (reported)
    Dec 23, 2025
    Owned after transaction
    286.4K shares
    Days from execution to publication
    6

    Calculation

    Value = shares × reported price per share

    • Shares: 5,000
    • Price: $1.02

    = $5,100

    What this establishes

    Bitterman Robert J filed this Form 4 reporting a open-market purchase of PHIO on Dec 23, 2025. It became public on Dec 29, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chairman, Pres. & CEO
    Bitterman Robert Jcik:0001304395
    Issuer
    Phio Pharmaceuticals Corp.cik:0001533040

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.